Baseline Characteristics of Participants in the ASPREE (ASPirin in Reducing Events in the Elderly) Study.

ABSTRACT:

Background

There are no primary prevention trials of aspirin with relevant geriatric outcomes in elderly people. ASPirin in Reducing Events in the Elderly (ASPREE) is a placebo-controlled trial of low-dose aspirin that will determine whether 5 years of daily 100-mg enteric-coated aspirin extends disability-free and dementia-free life in a healthy elderly population and whether these benefits outweigh the risks.

Methods

Set in primary care, this randomized double-blind placebo-controlled trial has a composite primary endpoint of death, incident dementia or persistent physical disability. Participants aged 70+ years (non-minorities) or 65+ years (U.S. minorities) were free of cardiovascular disease, dementia, or physical disability and without a contraindication to, or indicat

SUBMITTER: McNeil JJ 

PROVIDER: S-EPMC5861878 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature